MOORE ALISON — SEC insider filings
SEC reporting owner CIK 1754937. 26 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2020-08-14 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 11 legs across 9 filings — 166,325 shares, $5,434,421 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 44,574 shares @ $40.00 ($1,782,960) in Allogene Therapeutics, Inc., filed 2020-10-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | Chief Technical Officer | 10 | — | 7 legs · 139,274 sh · $5,393,060 | 18 |
| CODEXIS, INC. (CDXS) | President and CEO, Director | 12 | — | 4 legs · 27,051 sh · $41,361 | 11 |
| Artiva Biotherapeutics, Inc. (ARTV) | Director | 4 | — | — | 4 |
Insider filings — MOORE ALISON
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | CODEXIS, INC. (CDXS) | Sale (S): 10,651 @ $1.14 | EDGAR |
| 2026-10-14 | 4 | CODEXIS, INC. (CDXS) | Sale (S): 6,335 @ $1.36 | EDGAR |
| 2026-09-14 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Grant/award (A): 16,250 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Grant/award (A): 13,750 (derivative) @ $0 | EDGAR |
| 2026-02-25 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 993,000 (derivative) @ $0 | EDGAR |
| 2026-02-09 | 4 | CODEXIS, INC. (CDXS) | Sale (S): 3,826 @ $1.31 | EDGAR |
| 2025-11-17 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 85,000 @ $0 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | CODEXIS, INC. (CDXS) | Sale (S): 6,239 @ $2.51 | EDGAR |
| 2025-06-26 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Grant/award (A): 13,750 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 26,875 @ $0 · Grant/award (A): 161,250 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4 | Artiva Biotherapeutics, Inc. (ARTV) | Grant/award (A): 27,500 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 50,000 @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 30,120 @ $0 | EDGAR |
| 2023-06-15 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 34,602 @ $0 | EDGAR |
| 2023-03-24 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 558,094 @ $0 · Grant/award (A): 432,738 (derivative) @ $0 | EDGAR |
| 2023-03-16 | 4 | Allogene Therapeutics, Inc. (ALLO) | Tax withholding (F): 8,351 @ $5.51 | EDGAR |
| 2022-06-16 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 11,273 @ $0 | EDGAR |
| 2022-03-25 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 737,179 (derivative) @ $0 | EDGAR |
| 2022-03-17 | 4 | Allogene Therapeutics, Inc. (ALLO) | Sale (S): 8,698 @ $7.63 | EDGAR |
| 2021-06-17 | 4 | CODEXIS, INC. (CDXS) | Grant/award (A): 4,796 @ $0 | EDGAR |
| 2021-03-30 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 24,866 @ $0 · Grant/award (A): 92,365 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | Allogene Therapeutics, Inc. (ALLO) | Sale (S): 6,164 @ $38.14 | EDGAR |
| 2020-10-13 | 4 | Allogene Therapeutics, Inc. (ALLO) | Option exercise (M): 24,233 @ $2.27 · Sale (S): 24,233 @ $42 · Option exercise (M): 11,031 @ $2.27 · Sale (S): 11,031 @ $42 · Option exercise (M): 24,233 (derivative) @ $0 · Option exercise (M): 11,031 (derivative) @ $0 | EDGAR |
| 2020-10-09 | 4 | Allogene Therapeutics, Inc. (ALLO) | Option exercise (M): 5,065 @ $2.27 · Sale (S): 5,065 @ $41 · Option exercise (M): 30,199 @ $2.27 · Sale (S): 39,509 @ $41 · Option exercise (M): 5,065 (derivative) @ $0 · Option exercise (M): 30,199 (derivative) @ $0 | EDGAR |
| 2020-10-08 | 4 | Allogene Therapeutics, Inc. (ALLO) | Option exercise (M): 35,264 @ $2.27 · Sale (S): 44,574 @ $40 · Option exercise (M): 35,264 (derivative) @ $0 | EDGAR |
| 2020-08-14 | 4 | Allogene Therapeutics, Inc. (ALLO) | Option exercise (M): 32,451 @ $2.27 · Option exercise (M): 32,451 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1754937 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs